Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer

Peter Black, MD
Published: Friday, Jul 21, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.

Durvalumab is approved for use in patients with locally advanced or metastatic bladder cancer who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

In addition to treating patients, durvalumab has brought a lot of industry and research interest to bladder cancer, says Black.


Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.

Durvalumab is approved for use in patients with locally advanced or metastatic bladder cancer who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

In addition to treating patients, durvalumab has brought a lot of industry and research interest to bladder cancer, says Black.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x